|
Variable
|
Number (%)
|
EGFR
|
Univariate
|
Multivariate
|
|---|
|
Mutation (%)
|
Wild type (%)
|
Odds ratio (95 % CI)
|
p value
|
Odds ratio (95 % CI)
|
p value
|
|---|
|
Gender
|
|
Male
|
334 (67.61)
|
108 (32.34)
|
226 (67.66)
|
Ref.
| |
Ref.
| |
|
Female
|
160 (32.39)
|
68 (42.50)
|
92 (57.50)
|
1.55 (1.05–2.28)
|
0.028
|
0.64 (0.32–1.28)
|
0.209
|
|
Age
|
|
≤65
|
271 (54.86)
|
122 (45.02)
|
149 (54.98)
|
2.56 (1.73–3.78)
|
<0.001
|
2.51 (1.65–3.81)
|
<0.001
|
|
>65
|
223 (45.14)
|
54 (24.22)
|
169 (75.78)
|
Ref.
| |
Ref.
| |
|
Smoking history
|
|
Ever smoker
|
348 (70.45)
|
102 (29.31)
|
246 (70.69)
|
Ref.
| |
Ref.
| |
|
Never smoker
|
146 (29.55)
|
74 (50.68)
|
72 (49.32)
|
2.48 (1.66–3.69)
|
<0.001
|
3.63 (1.83–7.19)
|
<0.001
|
|
Never smoker
|
|
Male
|
21 (14.38)
|
11 (52.38)
|
10 (47.62)
|
Ref.
| | | |
|
Female
|
125 (85.62)
|
63 (50.40)
|
62 (49.60)
|
0.92 (0.37–2.33)
|
0.867
| | |
|
Pathologic stage
|
|
I + II
|
171 (34.62)
|
55 (32.16)
|
116 (67.84)
|
Ref.
| |
Ref.
| |
|
III + IV
|
323 (65.38)
|
121 (37.46)
|
202 (62.54)
|
1.26 (0.85–1.87)
|
0.243
|
1.45 (0.94– 2.24)
|
0.089
|
|
Pathology
|
|
Non-ADC
|
184 (32.75)
|
35 (19.02)
|
149 (80.98)
|
Ref.
| |
Ref.
| |
|
ADC
|
310 (62.75)
|
141 (45.48)
|
169 (54.52)
|
3.55 (2.31–5.46)
|
<0.001
|
3.57 (2.28–5.61)
|
<0.001
|
|
Male
|
212 (68.39)
|
86 (40.57)
|
126 (59.43)
|
Ref.
| | | |
|
Female
|
98 (31.61)
|
55 (56.12)
|
43 (43.88)
|
1.87 (1.15–3.04)
|
0.011
| | |
|
Never smoker ADC
|
|
Male
|
15 (16.13)
|
9 (60.00)
|
6 (40.00)
|
Ref.
| | | |
|
Female
|
78 (83.87)
|
51(65.38)
|
27(34.62)
|
1.26 (0.41–3.91)
|
0.69
| | |
|
Differentiation
|
|
Well
|
145 (29.35)
|
50 (34.48)
|
95 (65.52)
|
Ref.
| |
Ref.
| |
|
Moderate
|
249 (50.40)
|
92 (36.95)
|
157 (63.05)
|
1.11 (0.73–1.71)
|
0.623
|
1.14 (0.72–1.82)
|
0.573
|
|
Poor
|
97 (19.64)
|
34 (35.05)
|
63 (64.95)
|
1.03 (0.60–1.76)
|
0.927
|
1.10 (0.60–2.00)
|
0.759
|
-
EGFR epidermal growth factor receptor, NSCLC non-small cell lung cancer, ADC adenocarcinoma, CI confidence interval, Ref. reference group
